Drugs / 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06465914 | Jul 2024 → Jul 2027 expected | anus cancer, carcinoma, common wart, penile cancer +2 | Shanghai Bovax Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465914 ↗ |
| Modality | Vaccine | “9-valent HPV vaccine” NCT06465914 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection in the deltoid muscle” NCT06465914 ↗ |